BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 34310112)

  • 1. Chemosensitization of Temozolomide-Resistant Pediatric Diffuse Midline Glioma Using Potent Nanoencapsulated Forms of a N(3)-Propargyl Analogue.
    Heravi Shargh V; Luckett J; Bouzinab K; Paisey S; Turyanska L; Singleton WGB; Lowis S; Gershkovich P; Bradshaw TD; Stevens MFG; Bienemann A; Coyle B
    ACS Appl Mater Interfaces; 2021 Aug; 13(30):35266-35280. PubMed ID: 34310112
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Delivery of Temozolomide and N3-Propargyl Analog to Brain Tumors Using an Apoferritin Nanocage.
    Bouzinab K; Summers HS; Stevens MFG; Moody CJ; Thomas NR; Gershkovich P; Weston N; Ashford MB; Bradshaw TD; Turyanska L
    ACS Appl Mater Interfaces; 2020 Mar; 12(11):12609-12617. PubMed ID: 32073826
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preclinical evaluation of convection-enhanced delivery of liposomal doxorubicin to treat pediatric diffuse intrinsic pontine glioma and thalamic high-grade glioma.
    Sewing ACP; Lagerweij T; van Vuurden DG; Meel MH; Veringa SJE; Carcaboso AM; Gaillard PJ; Peter Vandertop W; Wesseling P; Noske D; Kaspers GJL; Hulleman E
    J Neurosurg Pediatr; 2017 May; 19(5):518-530. PubMed ID: 28291423
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Prognostic Impact of Radiotherapy in Conjunction with Temozolomide in Diffuse Intrinsic Pontine Glioma: A Systematic Review and Meta-Analysis.
    Shi S; Lu S; Jing X; Liao J; Li Q
    World Neurosurg; 2021 Apr; 148():e565-e571. PubMed ID: 33476781
    [TBL] [Abstract][Full Text] [Related]  

  • 5. β-catenin contributes to cordycepin-induced MGMT inhibition and reduction of temozolomide resistance in glioma cells by increasing intracellular reactive oxygen species.
    Bi Y; Li H; Yi D; Bai Y; Zhong S; Liu Q; Chen Y; Zhao G
    Cancer Lett; 2018 Oct; 435():66-79. PubMed ID: 30081068
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Methionine restriction of glioma does not induce MGMT and greatly improves temozolomide efficacy in an orthotopic nude-mouse model: A potential curable approach to a clinically-incurable disease.
    Kubota Y; Aoki Y; Masaki N; Obara K; Hamada K; Han Q; Bouvet M; Tsunoda T; Hoffman RM
    Biochem Biophys Res Commun; 2024 Feb; 695():149418. PubMed ID: 38176171
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Injectable postoperative enzyme-responsive hydrogels for reversing temozolomide resistance and reducing local recurrence after glioma operation.
    Zhao Z; Shen J; Zhang L; Wang L; Xu H; Han Y; Jia J; Lu Y; Yu R; Liu H
    Biomater Sci; 2020 Sep; 8(19):5306-5316. PubMed ID: 32573615
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Temozolomide loaded PLGA-based superparamagnetic nanoparticles for magnetic resonance imaging and treatment of malignant glioma.
    Ling Y; Wei K; Zou F; Zhong S
    Int J Pharm; 2012 Jul; 430(1-2):266-75. PubMed ID: 22486964
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The distribution, clearance, and brainstem toxicity of panobinostat administered by convection-enhanced delivery.
    Singleton WGB; Bienemann AS; Woolley M; Johnson D; Lewis O; Wyatt MJ; Damment SJP; Boulter LJ; Killick-Cole CL; Asby DJ; Gill SS
    J Neurosurg Pediatr; 2018 Sep; 22(3):288-296. PubMed ID: 29856296
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Regulation of temozolomide resistance in glioma cells via the RIP2/NF-κB/MGMT pathway.
    Hu YH; Jiao BH; Wang CY; Wu JL
    CNS Neurosci Ther; 2021 May; 27(5):552-563. PubMed ID: 33460245
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preclinical evaluation of binimetinib (MEK162) delivered via polymeric nanocarriers in combination with radiation and temozolomide in glioma.
    Bikhezar F; de Kruijff RM; van der Meer AJGM; Torrelo Villa G; van der Pol SMA; Becerril Aragon G; Gasol Garcia A; Narayan RS; de Vries HE; Slotman BJ; Denkova AG; Sminia P
    J Neurooncol; 2020 Jan; 146(2):239-246. PubMed ID: 31875307
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intranasal Delivery of Temozolomide-Conjugated Gold Nanoparticles Functionalized with Anti-EphA3 for Glioblastoma Targeting.
    Wang L; Tang S; Yu Y; Lv Y; Wang A; Yan X; Li N; Sha C; Sun K; Li Y
    Mol Pharm; 2021 Mar; 18(3):915-927. PubMed ID: 33417456
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Magnolol and Temozolomide exhibit a synergistic anti-glioma activity through MGMT inhibition.
    Kundu M; Das S; Nandi S; Dhara D; Mandal M
    Biochim Biophys Acta Mol Basis Dis; 2023 Oct; 1869(7):166782. PubMed ID: 37286145
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Controlled release of liposome-encapsulated temozolomide for brain tumour treatment by convection-enhanced delivery.
    Lin CY; Li RJ; Huang CY; Wei KC; Chen PY
    J Drug Target; 2018 Apr; 26(4):325-332. PubMed ID: 28911239
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diffuse intrinsic pontine glioma treated with prolonged temozolomide and radiotherapy--results of a United Kingdom phase II trial (CNS 2007 04).
    Bailey S; Howman A; Wheatley K; Wherton D; Boota N; Pizer B; Fisher D; Kearns P; Picton S; Saran F; Gibson M; Glaser A; Connolly DJ; Hargrave D
    Eur J Cancer; 2013 Dec; 49(18):3856-62. PubMed ID: 24011536
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Certain imidazotetrazines escape O6-methylguanine-DNA methyltransferase and mismatch repair.
    Zhang J; Stevens MF; Hummersone M; Madhusudan S; Laughton CA; Bradshaw TD
    Oncology; 2011; 80(3-4):195-207. PubMed ID: 21720182
    [TBL] [Abstract][Full Text] [Related]  

  • 17. N3-substituted temozolomide analogs overcome methylguanine-DNA methyltransferase and mismatch repair precipitating apoptotic and autophagic cancer cell death.
    Zhang J; Hummersone M; Matthews CS; Stevens MF; Bradshaw TD
    Oncology; 2015; 88(1):28-48. PubMed ID: 25277441
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Encapsulation of Temozolomide in a Calixarene Nanocapsule Improves Its Stability and Enhances Its Therapeutic Efficacy against Glioblastoma.
    Renziehausen A; Tsiailanis AD; Perryman R; Stylos EK; Chatzigiannis C; O'Neill K; Crook T; Tzakos AG; Syed N
    Mol Cancer Ther; 2019 Sep; 18(9):1497-1505. PubMed ID: 31213505
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The nanoprodrug of polytemozolomide combines with MGMT siRNA to enhance the effect of temozolomide in glioma.
    Xu H; Zhang Y; Li L; Ren Y; Qian F; Wang L; Ma H; Quan A; Liu H; Yu R
    Drug Deliv; 2023 Dec; 30(1):1-13. PubMed ID: 36579448
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pseudoprogression in children, adolescents and young adults with non-brainstem high grade glioma and diffuse intrinsic pontine glioma.
    Carceller F; Fowkes LA; Khabra K; Moreno L; Saran F; Burford A; Mackay A; Jones DT; Hovestadt V; Marshall LV; Vaidya S; Mandeville H; Jerome N; Bridges LR; Laxton R; Al-Sarraj S; Pfister SM; Leach MO; Pearson AD; Jones C; Koh DM; Zacharoulis S
    J Neurooncol; 2016 Aug; 129(1):109-21. PubMed ID: 27180091
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.